FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.
You may also be interested in...
For Wyeth, More Delays And Setbacks
Phase III methylnaltrexone study fails to show benefit over placebo, as Wyeth also pulls Pristiq’s EU vasomotor symptoms application.
For Wyeth, More Delays And Setbacks
Phase III methylnaltrexone study fails to show benefit over placebo, as Wyeth also pulls Pristiq’s EU vasomotor symptoms application.
FDA Clears Wyeth’s Pristiq For Depression
New study in menopausal hot flashes and night sweats is due first half of this year.